Posted on

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program

VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the Company’s wholly-owned subsidiary Optimi Labs Inc. to a list of approved suppliers under the Special Access Program (SAP). With a mission to provide compassionate, frontline solutions to Canada’s growing mental health crisis, the Company plans to supply psychedelics like psilocybin to those truly in need.

Announced on January 5, 2022, the SAP allows qualified medical practitioners to request access to Schedule 3 controlled substances such as psilocybin on a case-by-case emergency basis. Prior to the new regulatory amendments, medical practitioners were prohibited from requesting access to psilocybin and MDMA for individual psychedelic-assisted psychotherapy. The amendments have the potential to positively affect the lives of people experiencing serious mental health conditions and end-of-life distress when other therapies have failed, are unsuitable or are unavailable in Canada.

Optimi’s CEO, Bill Ciprick, says the SAP is already having a positive impact on patients in need and will provide the Company with the right avenue to develop and supply the demand for natural psilocybin.

“Optimi is committed to bringing transformative change to those suffering from debilitating palliative and non-palliative mental health trauma,” said Ciprick. “We will leave no stone unturned in our effort to provide the safest and most efficacious natural psilocybin product in the world, because frankly we need to get this right for those depending on us for support and healing.”

“Between the science, research, and good manufacturing practices, the SAP is an excellent opportunity for all of us to learn, grow and expand our knowledge capacity and improve treatment outcomes for many people in the years to come,” added Ciprick.

With the Company’s Dealer’s License approved by Health Canada earlier this month, Optimi has received requests for supply agreements from potential partners interested in the Company’s new EU-GMP compliant 10,000 sq. ft. facility located in Princeton, British Columbia. Once fully commercialized, the production facility will position Optimi as a global frontrunner in the cultivation, extraction, and vertical integration of high-grade all-natural psilocybin.

“Establishing Optimi’s presence in the psychedelic market begins with trust, which we believe we have earned through our in-house expert research and world-class advisory team, and by setting the gold standard in GMP compliance,” added JJ Wilson, Optimi’s Chairman of the Board.

Optimi plans to host a grand opening of its new facility this May and is committed to building awareness and education about the benefits of the SAP to physicians qualified to recommend the program to patients.

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

HAVN Life Enters Into Distribution Agreement With Mycrodose Therapeutics for U.S. Market

HAVN Life Enters Into Distribution Agreement With Mycrodose Therapeutics for U.S. Market

The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market

Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is thrilled to announce its entry into an exclusive U.S. Distribution Agreement (the “Exclusive Distribution Agreement”) with California-based Mycrodose Therapeutics Inc. (“Mycrodose”), a leading pharmaceutical company in the U.S. specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III drugs and other compounds aimed at treating cancer related conditions, mental health, and cognitive degenerative diseases.

HAVN Life and Mycrodose have entered into the Exclusive Distribution Agreement to facilitate the import of HAVN Life’s naturally derived GMP psilocybin into the United States for authorized research purposes. The Exclusive Distribution Agreement allows HAVN Life & Mycrodose to provide naturally derived GMP psilocybin to research institutions/researchers within the U.S. at competitive prices, which should assist with alleviating the supply chain issues currently facing researchers who are unable to find GMP psilocybin at an affordable price.

“HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics,” says HAVN Life CEO, Tim Moore. “We’ve been working closely with Chad and his team, and are excited about the potential of this partnership.”

Mycrodose is one of only a handful of pharmaceutical companies that has been authorized by the United States Drug Enforcement Agency (“DEA”), State of California Attorney General’s Research Advisory Board, and The Food & Drug Administration (“FDA”) to import and research six (6) Schedule I, II and III compounds. In December 2021, Mycrodose added a Schedule I Import license which allows the import of Schedule I psilocybin and psilocin.
DEA import authorization gives Mycrodose the ability to import the controlled substance of psilocybin and psilocin for clinical trials, research and development, analytical purposes, and distribution to its clients for authorized research purposes.

“Our company’s proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose’s ability to lead the U.S.-Pharmaceutical sector working with these highly controlled-substances here in the United States,” says Chad Conner, Chief Executive Officer of Mycrodose Therapeutics. “This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company working with this Schedule I compound. Mycrodose is dedicated to advancing research within this sector and this is one of many ways that we are helping,” he adds.

The interest and demand for psilocybin research in the United States has grown significantly in 2021 and continues to outpace supply in 2022. Recently the Drug Enforcement Agency (DEA) again increased the quota for psilocybin research in the U.S. HAVN and Mycrodose have already successfully completed a first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States, and Mycrodose is actively handling new enquiries from approved DEA licensed institutions and research organizations.

HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybe mushrooms.
For more information on obtaining naturally derived GMP psilocybin contact Mycrodose Therapeutics at www.MycrodoseThera.com

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for investigational research in an effort to define the future of modern medicine. HAVN Life offers a full range of high-quality mushroom and plant extracts that help support immune function and support a healthy lifestyle.

Purchase our plant-based Natural Health Products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About Mycrodose Therapeutics
Mycrodose Therapeutics Inc. is a U.S.-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing DEA Schedule I-III drugs and other compounds to treat cancer related conditions, mental health, and cognitive degenerative diseases. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

Contact:

Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Exclusive Distribution Agreement, Mycrodose’s business, products and future of Mycrodose’s business and the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the anticipated benefits from the Exclusive Distribution Agreement will not be realized as contemplated, or at all, risks that Mycrodose’s products and plan will vary from those stated in this news release and Mycrodose may not be able to carry out its business plans as expected and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.LinkedInFacebookTwitterEmailShare

Posted on

Numinus Appoints New Bioscience Advisors to Advance IP Development

Numinus Appoints New Bioscience Advisors to Advance IP Development

Advisors lead their fields in patent law, nutraceuticals & ethnobotany

VANCOUVER, BC, Feb. 1, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the appointment of three key advisors to its new Bioscience Advisory Board.

“We are delighted to welcome these experts to our advisory team,” said Sharan Sidhu, Numinus’ Science Officer and General Manager. “These appointments point to the rigour of the research and development that Numinus has already completed and indicate the compelling IP strategy and milestones we anticipate in 2022 and beyond. We look forward to gathering strategic insights from our advisors to help us advance our project pipeline.”

The following advisors have been appointed:

Graham Pechenik (JD) – Patent Attorney & Founder, Calyx Law

Mr. Pechenik is a registered patent attorney and the founder of Calyx Law, an industry-leading law firm specialized in IP relating to cannabis and psychedelics. Mr. Pechenik has a BS from UC San Diego, choosing Cognitive Neuroscience and Biochemistry majors after his first psychedelic experiences inspired deep curiosity about the bases for changes in consciousness; and a JD from New York University, where he initially pursued interests in bioethics and cognitive liberty. After a decade obtaining and defending patents for Fortune 500 companies across the agricultural, chemical, pharmaceutical, biotech, and technology industries, including working on several landmark patent cases both at trial and on appeal, Mr. Pechenik started Calyx Law to help cannabis and psychedelics ventures design and implement their IP strategies. Mr. Pechenik also contributes to Psilocybin Alpha as editor-at-large, writing about psychedelics IP and contributing to psychedelics patent, legalization, and decriminalization trackers, and is a member of Chacruna’s Council for the Protection of Sacred Plants.

Dr. Paul Spagnuolo (PhD) – Associate Professor, University of Guelph

Dr. Spagnuolo is an associate professor at the University of Guelph and past assistant professor at the University of Waterloo, specialized and award-winning in the development of nutraceuticals as novel therapeutics using cellular biology. He is a past member of the Natural Health Products Research Society of Canada and has received funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). Dr. Spagnuolo’s research focuses on understanding the therapeutic potential of nutraceuticals (i.e. foods that provide medical or health benefits) and has included investigation of anti-cancer effects in certain compounds. He is experienced in developing novel, multidisciplinary techniques that combine drug discovery platforms traditionally used in the pharmaceutical industry with new areas of study.

Dr. Cory Harris (PhD) – Associate Professor, University of Ottawa

Dr. Harris is an associate professor at the University of Ottawa, specialized in the ethnobotany, chemistry and bioactivity of plants. His work involves collaboration with Inuit and First Nations communities, and projects have included investigating the ethical and evidence-based use of alternative medicines and the health benefits and risks of wild plant foods. Dr. Harris also heads a graduate research community that undertakes special interest projects, operating out of UOttawa and supported by NSERC, Mitacs and the Province of Ontario.

“As Numinus Bioscience continues to demonstrate leadership in developing novel products and processes, we see an opportunity to invite expert advisors to help us discover new areas for collaboration and innovation,” said Payton Nyquvest, Numinus’ Founder and CEO. “These appointments reflect our multidisciplinary thinking and intent to focus on natural products as a major component of our IP strategy, in addition to investigating defensible patent opportunities that support both long-term commercial scaling and safe and equitable access for the public.”

The new Bioscience Advisory Board will contribute strategically to advancing Numinus’ IP strategy, including product development and clinical trial activities out of the Company’s Health Canada-licensed research facility, Numinus Bioscience. It joins Numinus’ existing General and Clinical advisory boards, comprised of leading industry and subject-matter experts who have been selected to support corporate and therapeutic protocol development. Among them are Drs. Gabor Maté, Dennis McKenna and Zachary Walsh.

About Numinus

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research, and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. 

Learn more at numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event “may”, “will”, “should”, “could” or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

SOURCE Numinus Wellness Inc.

For further information: Investor Contact: Jamie Kokoska, Vice President, Investor Relations, jamie.kokoska@numinus.com; Media Contact, May Lee, Communications Manager, may.lee@numinus.com

Posted on

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

CAPE TOWN, SA / ACCESSWIRE / February 1, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso™ is pleased to announce the launch of its single-serve Super Booster Functional Mushroom Sachets and Active CBD Sachets.

Medspresso™ has sourced the highest quality raw materials and ingredients for the new lines. The products are ethically sourced, compliant to the highest food standards, and contain zero harmful additives, preservatives or psycho-active THC compounds. The amount of CBD in each product adheres to the legal limit allowed by South African law which amounts to 20 mg per person per day.

Both the CBD and Mushroom products are fully water-soluble and can be added to any hot or cold beverage in a convenient manner, or in the case of the mushroom sachet, enjoyed as a standalone tea. The new products fulfill the ever-growing demand for convenience which has become highly valued by CBD and mushroom health supplement consumers. The products are packaged in easy-to-open, one and two-gram sachets which can be stored and transported with ease.

“We are constantly looking at new and healthy ways to diversify Medspresso™’s portfolio and innovative product offerings for our customers. The introduction of the sachets allow customers a means to enjoy the incredible health benifits of CBD and functional mushrooms with such ease.” – says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

The sachets will be sold in retail-ready cartons of twenty sachets per unit. The consumer will have the choice to purchase their monthly supply immediately or buy it from select retailers and resellers in a single sachet format at the point of sale. The flexible nature of the product also sets the stage for various exciting co-branding opportunities with partnered beverage manufacturers, healthcare institutions, retailers as well as hospitality and tourism sectors.

“The new line of CBD and mushroom sachets is a step in the right direction when it comes to offering health and wellness to our ever growing customer base. We believe that the convenience of the single-serve sachets will allow new customers to try and love the product before they invest in larger quantities. The product will be available from our select resellers, online retailers as well as on the Medspresso website.” – says Jeff Robinson, CEO of M2Bio Sciences.

Mushroom Super Booster Sachets – Each sachet contains a mix of 100% natural Lion’s Mane, Turkey Tail, Cordyceps, and Reishi mushroom extract. Mushroom extracts have a much higher concentration of active compounds than the raw mushroom powder used in similar product offerings in the category. The extracts are created through a double extraction process, harnessing remarkably more bioavailability per dose, and in turn, the consumer is rewarded with a superior tasting product that is rapidly absorbed by the digestive system.

Active CBD Sachets – Each Active CBD sachet contains 20 mg of pharmaceutical grade CBD isolate, which is double the amount of similar CBD sachet offerings currently in the South African market. Medspresso prides itself on the quality and traceability of CBD used in all of its products for local and international CBD consumers. Only the purest CBD imported from Colorado, USA with legitimate certificates and licenses are used. The nano-emulsion formula used in the CBD isolate makes the CBD 100% water-soluble and easily absorbed through the gut, allowing the user to experience the full health benefits almost instantaneously. The powder itself is tasteless, odorless, and clear when mixed into the beverage, making for the perfect healthy addition without compromising the taste, color, and experience of the original beverage.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co

Follow us on Twitter: https://twitter.com/Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/686573/Medspresso-Launches-CBD-and-Functional-Mushroom-Single-Serve-Sachets

Posted on

Ehave Issues Shareholder Letter and Provides Corporate Update

Ehave Issues Shareholder Letter and Provides Corporate Update

MIAMI, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.

Dear Fellow Shareholders,

Ehave is focused on progressing Psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health led by technology. We have built a network of like-minded scientists and mental health professionals combined with technology, who share our mission to create safe and effective therapeutics by leveraging clinical data to help us address mental health issues to achieve optimal patient outcomes.

Why Ehave is Important In The Psychedelic Ecosystem

Before I discuss the upward inflection points Ehave achieved in 2021, I would like to provide a reminder of the problem we are targeting and our mission to impact it. At its core, the problem is simple – In America, 21% of U.S. adults experienced mental illness in 2020 (52.9 million people), 5.6% of U.S. adults experienced serious mental illness in 2020 (14.2 million people), 16.5% of U.S. youth aged 6-17 experienced a mental health disorder in 2016, 6.7% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2020, and suicide is the 2nd leading cause of death among people aged 10-34. We are confident in our ability to deliver solutions because we have built a team that understands the challenges facing mental health.

Reflecting on 2021, I am very grateful for the accomplishments and progress we have made. As much of the heavy lifting has been completed, I am more positive than ever on both Ehave and the opportunities that lie ahead. Last year was a foundational year that set the stage for Ehave by developing breakthrough products and assembling a talented and expert team to execute our strategy for the future. As we move forward in 2022, we find ourselves strategically positioned with a strengthened balance sheet, a deep bench of experienced industry professionals, an exceptional portfolio of products and services, and an opportunity to provide an increased quality of mental health through data based psychedelic medicine. With a great deal of the development accomplished, we plan to engage with what I believe will be yet another transformative year for the company as we move towards monetizing Ehave’s investments by licensing our technology to other enterprises in an effort to advance research and commercialization of psychedelics.

Mycotopia Therapies

On December 28, 2020 Ehave sold 100% of its Mycotopia Therapies (OTC: TPIA) subsidiary to 20/20 Global Inc. for $350,000 and 75.77% of 20/20 Global’s outstanding shares in order to maximize Mycotopia Therapies value for our shareholders. The company was subsequently renamed Mycotopia Therapies and is traded on OTC Markets under the symbol TPIA. Less than a year later, Mycotopia Therapies announced it had signed an LOI to explore a merger with Ei.Ventures that will form PSLY.COM in a $360 million transaction that includes applying to list the new company’s shares on NASDAQ. Fulfilling our promise to maximize Mycotopia Therapies value for our shareholders, Ehave announced plans to spin out 30% of its PSLY.COM holdings to Ehave shareholders on a pro-rata basis. We anticipate this happening in the first half of 2022.

Ei.Ventures’ flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psilocybin is legal. Ei.Ventures recently announced the acquisition of a 12×12 estate in The Sandbox, a virtual world where players can build, own, and monetize their gaming experiences on the Ethereum blockchain, which represents the third-largest land sale in the Metaverse valued at $2.22M. The land will be called PSLY.COM, the name of the soon-to-be merged company of Ei.Ventures with Mycotopia Therapies.

KetaDASH Home Delivery Service

Early in 2021, Ehave announced plans for KetaDASH, a platform for medical practitioners to administer ketamine intravenously to patients at home. KetaDASH has evolved into a managed service organization focused on the psychedelic sector, with the ability to help doctors increase both patients and the revenue, as well as expand and manage their practice. Widely used for pain after certain medical procedures, Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression. We believe Ketamine has rapid antidepressant properties in unipolar and bipolar depression. An antidepressant effect has been reported as soon as 40 minutes after ketamine infusions, which is why we are rolling out our ketamine home delivery platform. The backbone for KetaDASH will be Ehave’s expertise in the area of digital therapeutics, which has been developed through years of testing in the area of mental healthcare. Ehave’s digital therapeutics insight will empower patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

After years of continued work to develop its proprietary digital therapeutics technology, Ehave is ahead of other psychedelic companies that are in the process of building integrated technical platforms and comprehensive toolsets to deliver psychedelic inspired medicines and experiential therapies combined with digital therapeutics. Ehave also plans to launch brain mapping ketamine clinical trials using Brain Scientific technology in Miami with Tristar Wellness. The clinical trial, originally planned for year-end 2021, but delayed by Covid, will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders. We plan to utilize an Institutional Review Board, which will review all research involving human subjects and implement policies and procedures regarding such research.

KetaDASH offers Ehave shareholders our fastest path to becoming a revenue generating company. KetaDASH offers ketamine for treatment resistant depression, anxiety, PTSD, and other conditions. After a short telemedicine visit, an experienced nurse will arrive at your location of choice to administer the sublingual treatment. Ehave plans to start its KetaDASH service this month in the San Francisco and Sacramento California area. Through our agreement with the telemedicine platform getheally.com, KetaDASH will have access to doctors in all 48 continental states. This will allow us to scale KetaDASH and expand it quickly. It is important to note Ehave and KetaDASH comply with all federal regulations. In an effort to continue to be compliant, our business plan calls for pairing each patient with a nurse to administer the treatment. I would like to invite you to learn more about the products and services offered by KetaDASH at www.ketadash.com.

MegaTeam

Ehave’s MegaTeam assessment and rehabilitation products are built on established methodologies for the measurement of cognitive abilities in populations with attention deficit hyperactivity disorder (“ADHD”). The MegaTeam products embed cognitive assessment and rehabilitation tasks within an engaging video game environment. iOS/Android Versions are currently being added to play stores. Ehave’s Ninja Reflex is a video game intervention for kids with neurodevelopmental disorders.

Ehave has conducted two Clinical Trials at the Hospital for Sick Children in Toronto for its MegaTeam-videogame as an intervention/treatment for ADHD. One has been closed and the second is ongoing.

Our initial trial started in September, 2016 and ended in April, 2017 with a pilot study of 35 participants. The trial showed the longer you practice on the game, the better your ability to stop a speeded motor response is, and the better you get at manipulating information in short-term working memory. https://clinicaltrials.gov/ct2/show/NCT02827188.

Our second trial started April, 2018 and is ongoing under supervision of Dr. Jennifer Crosbie with over 100 patients recruited to date. The Clinical Trial was sponsored by The Hospital for Sick Children in Ontario, Canada and was titled Cognitive Restructuring in ADHD: Functional Training (CRAFT) study. The objective of the study was to develop a non-pharmacological intervention program for children with ADHD. The Canadian government invested over $1,000,000.00 in grants in this closed study. Investors can find more information on our Clinical Trial on the U.S. National Library of Medicine’s Clinical Trials website at https://clinicaltrials.gov/ct2/show/NCT03502239.

HPPD Study with University of Melbourne

In 2021 our research took us to the other side of the world as we announced a partnership with the University of Melbourne to gather data and bio-markers to target Hallucinogen Persisting Perception Disorder (“HPPD”). We look forward to continuing this partnership into 2022 and will look to create bio lines and a testing revenue model as well as screening products capable of indicating HPPD. Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. Ehave believes the key to widespread acceptance for psychedelics is a focus on the good as well as the bad, which is why we are investing in this series of studies on HPPD.

Currently, researchers at the University of Melbourne have completed the necessary documents required for university ethics approval for online study of HPPD, and are updating the ethics documents for re-submission before the pilot can take place This includes recruitment, plain language statement, consent form, and debriefing. The researchers have also submitted a full ethics application, and are awaiting a decision on minimal risk accreditation. They have received preliminary approval for the pilot project to be considered “low or negligible risk,” and received ethics board review feedback on the submission seeking clarification on the role of funders regarding data, as well as minor clarifications on surveys/tasks being used.

MetaHealthU

With the growing popularity of the Metaverse, we believe 2022 will be a great year for our MetaHealthU, a mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With Meta HealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), Doctors and Medical Labs. The app is available for iOS 11.0 or later, Android, and includes a “digital file cabinet” for medical records. Features include easy to use navigation and search capabilities for users to collect, file and tag their medical records on their mobile device. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet.

The social connectivity aspects of this version of the app usher in a new era of digital health where users create and become part of their ‘social health network’. Meta HealthU users can create their own health-oriented Campaigns and Challenges and invite their friends, family and colleagues to participate in these Campaigns and Challenges. Combining the social aspects of health with the ability for users to create their own health-related challenges and campaigns provides powerful incentives to be and to stay healthy. For example, users can chip in a participation fee in the form of OmPoints to a “Challenge Purse” and compete to win OmPoints from the purse. The digital wallet connectivity with the blockchain enables users to bundle and share their health records in a secure and seamless way while earning OmPoints. The digital wallet stores reward points users can accumulate by participating in health-related Campaigns and Challenges. Institutions, such as Hospitals and Pharmaceutical companies, can fund health-related campaigns or research, create cohorts and invite them to participate. Using the Campaign Wizz Bridge Application Dashboard, they can reward participants with OmPoints for taking part in clinical trials or for adopting a healthy lifestyle. Users will be able to redeem OmPoints they have accumulated over time for Amazon Gift Cards or other gift cards which they can use for purchases.

Our health wallet is based on MyEtherWallet which will in the future allow users to mint their health records as an NFT. The function of having an immutable record of ownership or agreement minted onto a blockchain has such rich potential to impact so many industries. The most exciting use cases beyond the current iteration of NFTs include medical records, clinical trial results, and retreat results.

Ehave Dashboard Is Now Part Of MetaHealthU

The Ehave Dashboard is our flagship product. Over the years it has evolved into a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. Through our technology we offer Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Ehave has developed a medical record exchange plugin that will allow patients to own their own healthcare records and work more closely with medical professionals and psychedelic researchers to target conditions that are poorly addressed by the healthcare system today, such as chronic diseases, treatment-resistant depression, and neurological disorders. Plans for 2022 include monetizing this asset. Ehave also formed a partnership for our Dashboard with Health Wizz, a Digital Healthcare IT venture focused on FHIR interoperability and employee wellness, and BurstIQ, the leading provider of blockchain-based data solutions for the healthcare industry. Ehave will use BurstIQ’s privacy-protecting technology to link clinical trial data using its Dashboard and AI to health data from various sources, including wearables, lab reports, and doctor and hospital visits. Ehave allows us to provide our Dashboard users an opportunity to manage their personal medical records and retrieve them through a dedicated instance on the AWS (Amazon Web Services) platform.

Also in 2022, Ehave plans to monetize the AI technology it licensed from Vastmindz to expand the Ehave Dashboard and Ehave Medical App offerings. The AI technology will provide the Ehave Dashboard and Ehave Medical App with the ability to identify an individual’s physiological condition, such as Heart Rate, Heart Rate Variability (HRV), Respiration Rate, Oxygen Saturation Level, and other vital statistics. These changes in physiological condition will be identified by extracting information about changes in light absorption on an individual’s facial skin. No different than taking a selfie, the changes are captured within the RGB pixel values of camera frames and converted into various physiological vitals utilizing Vastmindz proprietary AI.

In Closing

Also in 2021, Ehave appointed Jeffrey D. Kamlet, MD, FASAM, DABAM to the position of Chief Medical Officer. Dr. Kamlet brings more than 30 years of Internal Medicine, Addiction Medicine and Pain Management experience to Ehave. He has also served as a Principal Investigator on over 20 major pharmaceutical clinical trials.

Moving forward we will continue to pursue a listing on a Canadian Stock Exchange and uplisting to the OTCQB Exchange, both of which were delayed in 2021 due to Covid. We will also continue to pursue closing the acquisition of 100% of Moksha Digital Software Pvt. Ltd., a provider of medical imaging software and the creator of the FDA cleared CuriePACS and CurieRIS solutions.

Our diverse team is our strength. As a result, we actively promote diversity and inclusion in all our projects by ensuring minority, women-owned, and small business participation in our industry. In 2021, we announced our firm commitment to sustainability and corporate responsibility, and we believe non-financial factors, such as environmental, social, and governance are a major part of identifying material risks and growth opportunities.

We look forward to sharing our accomplishments in the coming year as we strive to create value for our customers, shareholders, and employees – and we thank all our stakeholders for their support of our mission.

Sincerely,

Ben Kaplan
Chief Executive Officer

About Ehave, Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investor Relations, please contact:

David Kugelman
(866) 692-6847
(404) 281-8556 Mobile and WhatsApp
Skype: kugsusa
ir@ehave.com

Posted on

MDMA Passport + Commercial LSD Study: issue 34

Hello and welcome back.

Who else is counting down the days til the Daily Mushroom + Entheon Biomedical Mental Health Town Hall?? If you haven’t registered yet, you can do so here. What are you waiting for? It’s totally free and virtual so anyone can attend.

Here’s what’s in store for you in today’s issue:

🍄 The psychedelic that’s already in our brains

🍄 MAPS receives Innovation Passport for MDMA therapy 🎉

🍄 First commercial study of LSD in 40 years

🍄 Will Oregon legalize microdosing?

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

7 days of tripping to heal mentally, physically and radically change a career path

In this episode of The Daily Mushroom Podcast, we have Cory Firth, Executive Director of The Canadian Psychedelic Association and founder of DoseDay! Cory opens about his battle with mental health and shares his experience with psychedelics in his quest to find meaning in his life. He also talks about how he got himself into a 7 ayahuasca retreat and what that journey gave him.

Therapeutic banner

First commercial study of LSD in 40 years

MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.

The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation. 

Shares of MNMD spiked 30% following the announcement 💰

Goodbye Blue Mondays

A recent study found pure MDMA administered in a clinic does not have the “come down” effect that recreational users often report the day after dosing. 

Participants maintained a positive mood during the week following the dose. Plus, no participant had used or desired to use illegal MDMA at the 3 month and 6 month follow ups.

Mario’s secret revealed 🍄

The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.

Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.

Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.

Maybe that’s why Mario can jump so high without destroying his joints 😉

inspirational banner

MAPS receives Innovation Passport for MDMA therapy 🎉

The Innovation Passport will make MDMA therapy for PTSD widely available in the UK, as rapidly as possible!

The Multidisciplinary Association for Psychedelic Studies (MAPS) found that 88% of patients had a reduction in PTSD symptoms after three MDMA sessions in conjunction with trauma-focused therapy. 

The organization was granted an Innovation Passport for the treatment – a UK designation that speeds up the timeline for approval of innovative medicines for life-threatening conditions (similar to Breakthrough Therapy Designations in the US, which the treatment received in 2017).

The psychedelic that’s already in our brains

Did you know that one of the most promising addiction treatments is a psychedelic compound that’s found throughout nature and is present within the human body?

It’s called DMT (N,N-Dimethyltryptamine) and is thought to be produced in the brain’s pineal gland. DMT is released in large amounts when we dream and when we die.  

Learn what leading DMT experts have discovered at the Daily Mushroom + Entheon Biomedical Mental Health Town Hall on Thursday, Feb. 3rd. Register now for free to get the inside scoop 👇

Donating psilocybin to patients in need

CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).

The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP. 

The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.

business banner

Beckley Psytech began training psychotherapists for a phase II study on 5-MeO-DMT for treatment-resistant depression through Fluence’s interactive training program. Within the next year, Beckley aims to train 80 psychotherapists on how to administer psychedelic therapy.

Mydecine (MYCO) is partnering with a UK-based charity called Combat Stress and the King’s College London to study psilocybin therapy as a treatment for veterans with severe, treatment-resistant PTSD. 

Psygen Labs entered into an agreement to supply Universal Ibogaine (IBO) with ibogaine for an upcoming clinical trial on opioid addiction.

atai Life Sciences (ATAI) launched a wholly owned platform company called Invyxis, which will focus on developing novel compounds that target serotonin 5-HT2A receptors.

Akome Biotech, a subsidiary of Core One Labs’ (COOL), signed a consulting agreement with the University of Barcelona to develop psychedelic treatments for depression, stroke, Parkinson’s, and Alzheimer’s.

Ketamine One (MEDI) changed its name to Wellbeing Digital Sciences and partnered with Nova Mentis (NM) to study psilocybin microdosing for fragile x syndrome.

legal banner

Oregon is on track to provide legal psilocybin services in 2023

But one question remains unanswered: will the new program include microdosing?

For the past year, the Oregon Health Authority has been planning the regulatory framework to implement Measure 109, which legalized psilocybin sessions under the care of licensed facilitators. The program is on schedule to roll out at the beginning of 2023.

At the latest public Zoom meeting, a push to include microdosing in the program received backlash from some advisory board members, but others thought it was worth considering. Members have until the end of June to reach a consensus.

 

Two psilocybin bills filed in Oklahoma

The first bill would promote research focused on treating depression and anxiety in veterans. The second would promote research into 10 different conditions and reduce the penalty for psilocybin possession to a fine.

Video of the Week

The Battle Over Psychedelic Therapy’s Future

Playlist of the Week

Trippy Songs 🍄🍃👽🚀
Posted on

Donating psilocybin to patients in need

Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program

CCrest Laboratories is donating psilocybin truffles so patients in need can access the medicine for free through Canada’s Special Access Program (SAP).

The company was just approved as a licensed psilocybin producer by Health Canada, along with Numinus Wellness (NUMI) and Filament Health’s (FH) Psilo Scientific, allowing them to supply psilocybin for clinical trials and emergency treatments through the SAP. 

The truffles will be grown by Red Light Holland (TRUFF) and tested at CCrest Labs before being donated as part of their “compassionate need and free supply” approach.

Red Light Holland Corp.

PDF of article

Posted on

Doseology Names CFO and Appoints New Board Member

Doseology Names CFO and Appoints New Board Member

Vernon, British Columbia, January 28, 2022 – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”), a British Columbia-based diversified life sciences company developing mushroom-based health and wellness solutions, announces the appointment of Peter Geh as Chief Financial Officer, effective January 26, 2022, and the addition of Harbir Toor as Director and Independent Audit Chair, effective January 27, 2022.

Peter Geh is an experienced financial and accounting executive based in Kelowna, B.C. As a Chartered Professional Accountant with over fifteen years of corporate experience, he has guided several Canadian companies through growth stages in the healthtech, retail, and manufacturing industries.

Peter spent over ten years in public practice accounting working with entities in the public, private and not-for-profit sectors. As VP Finance of a Canadian tech company, Peter oversaw revenue growth of over 400 percent and staff growth of 75 percent during a two-year period.

“We’re very fortunate to have Peter join our team at this critical stage”, said Maryam Marissen, Doseology CEO. “His experience across several related industries in British Columbia, plus his ability to hone in on financial details while maintaining high-level perspective make him the ideal CFO for Doseology.”

On the appointment, Peter Geh remarked, “I am very excited about the opportunity to be a part of such an innovative, growing company like Doseology. To help guide us forward, I plan to leverage my specialties in strategic planning and execution, financial risk management, and shareholder value creation. I have a passion for helping companies of this size because I can take a very hands-on approach to financial management. I’m looking forward to working towards our goals with the Doseology team.”

Doseology Sciences Inc. has also named Harbir Toor, CPA, CA, as the Independent Audit Chair of the Board of Directors. Ms. Toor has 25 years of experience in strategic planning, risk management, governance, capital raises, and financial accounting. She began her career in audit at KPMG and most recently has held several senior executive positions in both private and publicly listed companies, including VP Finance and CFO in the biopharmaceutical and life sciences industries.

CEO Maryam Marissen commented, “Harbir is a tremendous asset for a diversified life sciences company such as ours. She has guided several other Canadian biotech and pharmaceutical companies in their financial and operational growth phases, and that relevant experience is truly invaluable.”

Ms. Marissen thanks Interim CFO Alex McAulay for his service to the Company. Doseology also announces that Mr. Gordon Jang has resigned as a Director and Independent Audit Chair of the Company, effective January 27, 2022. Mr. Jang will remain an advisor on Doseology’s financial matters and strategic decisions. Doseology wishes to thank Gordon for his valuable service and insight.

To support the Company’s mission and create profitable revenue streams in growing markets, Doseology is pursuing the cultivation of functional mushrooms, distribution of its medicinal mushroom nootropics products, and establishing clinical services. In November, the company applied for a Health Canada Dealer’s License, which upon approval will allow for psilocybin-related research and cultivation. 

To learn more about the Doseology management team and see recent company news, visit Doseology Investor Resources.

Maryam Marissen
Chief Executive Officer
Doseology Sciences Inc.
maryam@doseology.com

About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

For further information contact:
Investor Relations: investor@doseology.com
Media Inquiries: media@doseology.com
Telephone: 236-349-0064
Website: www.doseology.com

Forward Looking Statements
This corporate update contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES

Posted on

Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

Health Canada list identifies select companies that can supply psilocybin to approved applicants through the Special Access Program for patient treatment

VANCOUVER, BC, Jan. 27, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its research facility, Numinus Bioscience, has been included on Health Canada’s list of federally licensed psilocybin producers.

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with severe or life-threatening illness. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials.

“Through our inclusion, we look forward to collaborating with healthcare providers and other groups to ensure people in need receive efficacious treatments,” said Sharan Sidhu, Science Officer and General Manager, Numinus Bioscience.

At this time, Numinus Bioscience is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15 and 25mg of psilocybin. These doses are produced under Good Agricultural and Collection Practices and tested for potency and impurities to support patient safety and practitioner confidence. With sufficient clinical data, Numinus may also make available other products that are currently being developed in its IP pipeline, should those meet the standards identified by Health Canada. With its Dealer’s License and research facility, Numinus Bioscience is permitted to conduct several activities in addition to the production of psilocybin, including assembly, sale, export, analytical testing and R&D of ketamine, LSD and MDMA.

“Numinus is glad to see Health Canada committing to broadened mental healthcare access, starting with those in most need,” said Payton Nyquvest, CEO and Founder, Numinus. “As clinical evidence grows, we look forward to making more treatments available and further advancing the development of psychedelic therapies and mental health innovations.”

About Numinus
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. 
Learn more at numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event “may”, “will”, “should”, “could” or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

SOURCE Numinus Wellness Inc.

For further information: Investor Contact: Jamie Kokoska, Vice President, Investor Relations, jamie.kokoska@numinus.com; Media Contact: May Lee, Communications Manager, may.lee@numinus.com

Posted on

Mario’s secret revealed 🍄

Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada

The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.

Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.

Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.

Maybe that’s why Mario can jump so high without destroying his joints 😉

PDF of article